Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Blueprint Medicines Corp

BPMC
Current price
73.98 USD +0.9 USD (+1.23%)
Last closed 72.42 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 4 379 897 856 USD
Yield for 12 month +56.60 %
Week
Month
Year
BPMC
21.11.2021 - 28.11.2021

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Address: 45 Sidney Street, Cambridge, MA, United States, 02139

Analytics

WallStreet Target Price

79.5 USD

P/E ratio

Dividend Yield

Current Year

+204 036 000 USD

Last Year

+180 080 000 USD

Current Quarter

+56 566 000 USD

Last Quarter

+57 570 000 USD

Current Year

+186 223 000 USD

Last Year

+162 146 000 USD

Current Quarter

+52 013 000 USD

Last Quarter

+55 247 000 USD

Key Figures BPMC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -513 816 992 USD
Operating Margin TTM -228.02 %
PE Ratio
Return On Assets TTM -25.89 %
PEG Ratio
Return On Equity TTM -131.62 %
Wall Street Target Price 79.5 USD
Revenue TTM 216 204 000 USD
Book Value 3.34 USD
Revenue Per Share TTM 3.59 USD
Dividend Share
Quarterly Revenue Growth YOY -14.3 %
Dividend Yield
Gross Profit TTM 177 275 000 USD
Earnings Share -9.2 USD
Diluted Eps TTM -9.2 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -256.57 %

Dividend Analytics BPMC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BPMC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BPMC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 18.5307
Price Sales TTM 20.2582
Enterprise Value EBITDA -8.2325
Price Book MRQ 21.6443

Financials BPMC

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BPMC

For 52 weeks

37.82 USD 72.14 USD
50 Day MA 55.82 USD
Shares Short Prior Month 4 443 895
200 Day MA 52.93 USD
Short Ratio 4.51
Shares Short 4 167 360
Short Percent 9.24 %